Since XBP1 is a key molecule affecting tumor APVT formation, tumor growth and clinical prognosis of PCNSL patients, small molecules targeting this molecule might be able to prevent growth of the malignancy and improve clinical outcomes. The gene discussed is XBP1; the disease is primary central nervous system lymphoma.